Omalizumab, mepolizumab, reslizumab i benralizumab per al tractament de l'asma greu no controlada en pacients adults
Asthma is a syndrome that includes several clinical phenotypes that share similar clinical manifestations, but probably different etiologies. From a pragmatic point of view, it could be defined as a chronic inflammatory respiratory disease, in the pathogenesis of several cells and mediators of inflammation, partly conditioned by genetic factors, bronchial hyperresponse and a variable obstruction of the airflow, totally or partially reversible spontaneously or by drug action. It is estimated that in Spain asthma affects approximately 4.9% of adults and 10% of children.
Severe asthma; Pharmacological treatment; Adult patients
Programa d'harmonització farmacoterapèutica. Omalizumab, mepolizumab, reslizumab i benralizumab per al tractament de l'asma greu no controlada en pacients adults. Barcelona: Servei Català de la Salut; 2019.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/4266
This item appears in following collections
The following license files are associated with this item: